Abstract:Tumor microenvironment (TME) of a mature solid tumor is made of three components: tumor cell clusters or nests, stroma and immune cells. Most of the microvessels are located in the stroma, which is made of extracellular matrix and tumor associated fibroblasts (TAF). Circulating nanoparticles (NP) extravasating through the leaky microvessels first encounter the stroma and are taken up by TAF. SomeNPwill also penetrate through the stroma and reach tumor nests, depending on the particle size. In a stroma rich bladder cancer model, TAF are themajor cells taken up small LPC NP which contain ~80% cisplatin. Genome damaged TAF secrete Wnt16 which in a paracrine manner activates tumor cells for drug resistance and for epithelial-to-mesenchymal transition. It also induces neighboring naive fibroblast to become drug resistance and the endothelial cells to undergo angiogenesis. After repeated LPC administration, the bladder tumor becomes highlyWnt16 positive and highly drug resistant. Tumor rapidly regrows soon after LPC dosing is completed. Delivery of Wnt16 siRNA by LPH NP to the tumor can down-regulate Wnt16, inhibit the development of tumor drug resistance and enhance tumor growth inhibition by LPC. In advancedmurine B16F10melanoma, tumor does not contain a lot of stroma, and is relatively resistant to a nano-vaccine. LPH delivery of TGFβ siRNA, PLGA NP delivery of CDDO-Me (an anti-inflammatory) or Sunitinib (a broad-spectrum kinase inhibitor), or PEGylated curcumin micelles, can all downregulate the Th2 type cytokines, inhibit Treg cells and myeloid-derived suppressor cells and enhance tumor infiltrating CD8+ T-cells in the treated tumor. These immune modulators significantly enhance the tumor growth inhibition by a nano vaccine designed to boost the CTL response against the melanoma. Thus, we conclude that both siRNA and small molecule inhibitors can be delivered to modulate TME to facilitate either chemo or immune therapy, or both. Work supported by NIH grants CA149363, CA151652, CA149387 and DK100664.

Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy

Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy

Application of mPEG-CS-cRGD/Bmi-1RNAi-PTX nanoparticles in suppression of laryngeal cancer by targeting cancer stem cells

Nanomedicine Integrating the Lipidic Derivative of 5-Fluorouracil, Miriplatin and PD-L1 Sirna for Enhancing Tumor Therapy

Tumor-targeted Delivery of Sirna by Surface-Modified LPC Nanoparticles

Photosensitive and dual-targeted chromium nanoparticle delivering small interfering RNA YTHDF1 for molecular-targeted immunotherapy in liver cancer

Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers

Co-delivery of siRNA and cisplatin via electrospun Nanofibrous membranes for synergistic treatment of malignant melanoma

Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model

Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model

Tumor Microenvironment and Nanodrug Delivery

Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Cancer Therapy.

Targeted Anti-Cancer Therapy: Co-Delivery of VEGF siRNA and Phenethyl isothiocyanate (PEITC) via cRGD-Modified Lipid Nanoparticles for Enhanced Anti-Angiogenic Efficacy

Enhancing the Management of Metastatic Tumors by Robust Co‐delivery of 5‐fluorouracil/microRNA‐10b inhibitor Using EGFR‐targeted Nanovehicles

Dual Functional LipoMET Mediates Envelope-type Nanoparticles to Combinational Oncogene Silencing and Tumor Growth Inhibition

CAFs targeted ultrasound-responsive nanodroplets loaded V9302 and GLULsiRNA to inhibit melanoma growth via glutamine metabolic reprogramming and tumor microenvironment remodeling

Tumor-Targeted Codelivery of CpG and siRNA by a Dual-Ligand-Functionalized Curdlan Nanoparticle

Nanoparticles (NPs)-mediated Siglec15 silencing and macrophage repolarization for enhanced cancer immunotherapy

Brain Tumor-Targeted Therapy by Systemic Delivery of Sirna with Transferrin Receptor-Mediated Core-Shell Nanoparticles.

Ultrasound-Responsive Nanocarriers Delivering siRNA and Fe3O4 Nanoparticles Reprogram Macrophages and Inhibit M2 Polarization for Enhanced NSCLC Immunotherapy

Systemic siRNA Delivery with a Dual pH-Responsive and Tumor-targeted Nanovector for Inhibiting Tumor Growth and Spontaneous Metastasis in Orthotopic Murine Model of Breast Carcinoma